INFLUENZA TREATMENT IS ALWAYS IMPORTANT PROBLEM

The paper presents evidence of the need for constant monitoring flu incidence and the variability of the pathogen using genetic methods of research, which will record the circulation of resistant strains. Serotypes circulating strains are often a new to the human immune system. So there is no herd immunity to them. WHO recommends as influenza therapeutic agents of the first line amantadine, remantadin which are effective against the strains of influenza A viruses. Second line drugs are considered neuraminidase inhibitors (zanamivir, oseltamivir) which are effective against influenza viruses A and B. But the vast majority of human isolates of influenza viruses rapidly acquire resistance to remantadin, oseltamivir. The development of new chemotherapeutic agents for the causal treatment of influenza remains relevant task virology and medicine. Specific vaccination with vaccines containing current circulating strains, can be a very effective means for the groups with an increased risk of the disease. Combination of vaccination and the use of effective causal therapy will help to prevent the spread of influenza pandemics in the future.